関連する実験動画

Updated: Jan 23, 2026

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Published on: October 3, 2025

261

ディクティオステリウムDIRS-1のシーケンス:反転した末端のリピートと内輪交差点のシーケンスを持つ明らかなレトロトランポゾン

J Cappello, K Handelsman, H F Lodish

    Cell
    |November 1, 1985
    PubMed
    まとめ

    Dictyostelium discoideumのトランポゾンであるDIRS-1は,潜在的レトロトランポゾンであり,非同一の反転末端の繰り返しを持っています. その保存された読み取りフレームは,レトロウイルス逆転写酵素とのホモロジーを示し,新しい複製機構を示唆しています.

    さらに関連する動画

    siRNA - Small Interfering RNAs: Post-transcription Gene Silencing02:30

    siRNA - Small Interfering RNAs: Post-transcription Gene Silencing

    18.4K
    Small interfering RNAs siRNA02:30

    Small interfering RNAs siRNA

    4.3K

    関連する概念動画

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    219
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    261
    siRNA - Small Interfering RNAs02:30

    siRNA - Small Interfering RNAs

    Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
    In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
    18.4K
    Small interfering RNAs (siRNA)02:30

    Small interfering RNAs (siRNA)

    No description available
    4.3K
    Hepatic Portal System01:21

    Hepatic Portal System

    The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
    At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
    5.6K
    Hepatic Drug Excretion: Influencing Factors01:16

    Hepatic Drug Excretion: Influencing Factors

    The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
    539